Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma.
Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, Fredrick D, Atkins MB, Iafrate AJ, Flaherty KT, Mier JW, Sullivan RJ. Panka DJ, et al. Among authors: buchbinder e. Mol Cancer Ther. 2014 Dec;13(12):3210-8. doi: 10.1158/1535-7163.MCT-14-0349. Epub 2014 Oct 15. Mol Cancer Ther. 2014. PMID: 25319388 Free PMC article.
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. Sullivan RJ, et al. Among authors: buchbinder e. Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15. Cancer Discov. 2018. PMID: 29247021 Clinical Trial.
Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation.
Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Pike LRG, et al. Among authors: buchbinder e. Radiother Oncol. 2017 Jul;124(1):98-103. doi: 10.1016/j.radonc.2017.06.006. Epub 2017 Jun 26. Radiother Oncol. 2017. PMID: 28662869
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.
Ng TSC, Hu H, Kronister S, Lee C, Li R, Gerosa L, Stopka SA, Burgenske DM, Khurana I, Regan MS, Vallabhaneni S, Putta N, Scott E, Matvey D, Giobbie-Hurder A, Kohler RH, Sarkaria JN, Parangi S, Sorger PK, Agar NYR, Jacene HA, Sullivan RJ, Buchbinder E, Mikula H, Weissleder R, Miller MA. Ng TSC, et al. Among authors: buchbinder e. Sci Adv. 2022 Apr 29;8(17):eabl6339. doi: 10.1126/sciadv.abl6339. Epub 2022 Apr 29. Sci Adv. 2022. PMID: 35486732 Free PMC article.
126 results